Date: July 22 - 24, 2018
Location: New York Hilton Midtown Manhattan Hotel, New York, NY
This two-day workshop will provide an update on the progress in oral peptide delivery since the CRS Workshop on this topic in 2014. Select pharmacuetical companies will provide case studies of selected oral peptide candidates in preclinical and clinical development. Select academic and industrial scientists will discuss the integrated knowledge generated through large consortia, i.e. the TRANS-INT EU consortium.
Topics include:A realistic assessment of oral peptide formulation challenges and ways to overcome them The opportunities offered by chemistry modification, intestinal permeation enhancers, excipients, micro/nanotechnology, and combinations thereof and (iii) the translational possibilities.
Attendees will hear cutting edge science and will be able to discuss current progress with some of the leading industrial and academic researchers in oral peptides.
Date: Saturday July 21
Time: 8:30am - 5:00pm
Title: Oral Peptide Delivery: A Follow-up From CRS 2014
Featured Speaker: Ronak Savla (Catalent, NJ,) speaking on “Parallel screening approach for the oral delivery of peptides”
Date: Sunday July 22
Time: 8:00am - 12:30pm
Date: Monday July 23
Title: Inflection Point of Drug Formulation: Advanced in Silico Applications for Rational Drug Development
Moderator: Ronak Savla, Pharm.D., Ph.D. Scientific Affairs Manager, Catalent
Topics & Invited Speakers:
Modeling pharmacokinetic challenges of oral small molecules drugs- (pending presenter)
Molecular simulations of drug polymer interactions- Dr. Ronald G. Larson, Professor, Chemical Engineering, University of Michigan
Integrated pharmacokinetic modelling to guide formulation development- Jan Neelissen, Scientific Adviser, Catalent Pharma Solutions
Drug formulation is largely an empirical method that requires significant time, material, and labor. The next generation of drug delivery approaches, which need to overcome both physicochemical and biological barriers, will be found at the intersection of thorough understanding of biological mechanisms, incorporating pharmacokinetic and formulation considerations during drug molecule design, deciphering material chemistry, and advanced computer modeling. Harnessing the power of in silico modeling and simulation technologies along with in vitro studies will subtly shift the old ways of drug formulation, but cause profound impact. The result will be faster development, less attrition, reduced costs, and most importantly, better treatments for patients.
Title: Use of a Fiber-optic Low Volume Dissolution Technique to Quantitatively Measure the Delayed Release and Determination of Coating Level of Ibuprofen
Authors: Laura Hinett, Gregor McNeil
Title: Formulation Approaches to Reduce Unpleasant Side Effects of Omega-3 Fish Oil Soft Gelatin Capsules
Authors: Mohammad Harati, Doug Durham, and Christina Armstrong
Catalent’s Somerset, now home to our newest early phase development Center of Excellence, focusing on preclinical to clinical phase 2 formulation, analytical, and manufacturing solutions for orally delivered small molecules. We are excited to share our new and expanded capabilities with you!
To celebrate, you are invited to attend our tour and luncheon event.
Date: Wednesday July 25
Time: 10:00am - 1:30pm
14 Schoolhouse Rd
Somerset, NJ 08873
10:00am Arrival and refreshments
10:15am Welcome address
10:30am Early Development Strategies to Get to Phase I
11:00am DMPK Modeling for the Development of Controlled-Release Dosage Forms
11:40am Tour of facility
12:40pm Catered lunch
Joining us for the Controlled Release Society Meeting?
Transportation will be provided to and from the CRS main hotel (New York Hilton Midtown Manhattan)- departure will be at 8:15AM; please let us know if you require transportation by emailing email@example.com
Please RSVP by July 16, 2018